Patents by Inventor Antonio Cattaneo

Antonio Cattaneo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the potentiation of opioid analgesics effects on pain
    Patent number: 8715666
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: May 6, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • Analgesic treatment with prolonged effect
    Patent number: 8691221
    Abstract: Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: April 8, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • METHOD FOR THE POTENTIATION OF OPIOID ANALGESICS EFFECTS ON PAIN
    Publication number: 20120213784
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Application
    Filed: June 23, 2011
    Publication date: August 23, 2012
    Applicant: LAY LINE GENOMICS S.p.A.
    Inventors: FLAMINIA PAVONE, SARA MARINELLI, ANTONIO CATTANEO, GABRIELE UGOLINI
  • Novel Analgesic Treatment with Prolonged Effect
    Publication number: 20100291083
    Abstract: Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.
    Type: Application
    Filed: June 7, 2006
    Publication date: November 18, 2010
    Applicant: NOVARTIS VACCINES AND DIAGONOSTICS
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • Method for the humanization of antibodies and humanized antibodies thereby obtained
    Publication number: 20090300780
    Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.
    Type: Application
    Filed: December 23, 2004
    Publication date: December 3, 2009
    Inventors: Antonio Cattaneo, Doriano Lamba, Sonia Covaceuszach
  • Selection of intracellular immunoglobulins
    Patent number: 7569390
    Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 4, 2009
    Assignees: Medical Research Council, Scuola Internazionale Superiore Di Studi Avanzati
    Inventors: Tse Wai-Choi Eric, Terenos Rabbits, Antonio Cattaneo, Michela Visintin